PLK1 inhibition is lethal in K-RAS mutant cells as described in lung cancer [48], and in OC, synthetic lethality is produced with PLK1 inhibition and paclitaxel in CCNE1 amplified HGSC cells [49]. This evidence concerns the gene PLK1 and lung carcinoma.